

Curriculum Vitae Eva Maria König, PhD

PERSONAL DATA

<i>Name</i>	Eva Maria König, née Putz
<i>Citizenship</i>	Austria
<i>Date of birth</i>	6 th of August 1983
<i>Place of birth</i>	Bregenz, Austria
<i>Current work address</i>	Medical University of Vienna, Center for Physiology and Pharmacology Institute of Pharmacology, Waehringerstrasse 13A, A-1090 Vienna, Austria
<i>Marital status</i>	Married, two daughters (born 12/2017 and 06/2023)
<i>ORCID</i>	https://orcid.org/0000-0002-9990-4477
<i>Homepage</i>	https://evamkoenig727.wixsite.com/putz-koenig-lab
<i>E-mail</i>	eva-maria.koenig@meduniwien.ac.at

FIELDS OF RESEARCH

<i>Keywords</i>	immunology, tumor immunology, cell biology, natural killer (NK) cells, immunoediting, tumor evolution, cytokines, JAK/STAT/SOCS signaling, pharmacology, extracellular matrix, invasion and metastasis, leukemia, melanoma, cellular immunotherapy
-----------------	--

EDUCATION

2007-2013	PhD thesis (N094) at the Medical University of Vienna (MUW) under the supervision of Univ.-Prof. Dr. V. Sexl: Impact of IFNAR1 and STAT1-S727 on NK cell activity and tumor surveillance
2006-2007	Diploma thesis at the Max Perutz Laboratories, Vienna, under the supervision of a.o.Univ.-Prof. Dr. F. Pittner: Studies to develop a meat freshness sensor based on nanotechnology
2001-2007	Diploma studies of Chemistry at the University of Vienna
1994 – 2001	High school BG Bregenz Blumenstraße

EMPLOYMENTS

2024 – current	Principal Investigator at the Institute of Pharmacology, MUW, Vienna
2019 – 2023	Principal Investigator at the St. Anna Children’s Cancer Research Institute, Vienna
Apr. 2017 – Mar. 2018	Max Perutz Laboratories / Vetmeduni Vienna (Austria): Post-doctoral fellow in the laboratories of Prof. Thomas Decker (MFPL) and Prof. Veronika Sexl (Vetmeduni)
Mar. 2015 – Feb. 2017	QIMR Berghofer Institute of Medical Research (QLD, Australia): Post-doctoral fellow in the laboratory of Prof. Mark Smyth
Sept. 2013 – Feb. 2015	Vetmeduni Vienna (Austria): Post-doctoral fellow in the laboratory of Prof. Dr. V. Sexl
2007-2013	MUW/Vetmeduni Vienna (Austria): Pre-doctoral fellow in the laboratory of Prof. Dr. V. Sexl, supervision of trainees and diploma students
Sept.-Oct. 2005	Tecnuclear (Buenos Aires, Argentina): internship

ACADEMIC RECOGNITION

<i>Grants</i>	<p>2021: Stand-Alone Project, Austrian Science Fund (FWF P34832; 399,640 €; “Non-canonical STAT1 signaling in natural killer cells”; 01/2022-12/2025; project lead)</p> <p>2021: Fellingner Cancer Research Grant (25,000 €, “Uncovering immune evasion mechanisms of leukemic cells from natural killer cells”, 07/2021-06/2022, project lead)</p> <p>2021: DOC fellowship for my PhD student Michelle Buri, Austrian Academy of Sciences (155,500 €; “How do leukemic cells escape natural killer cell-mediated surveillance? Uncovering novel immune evasion mechanism(s)”; 08/2021-07/2024; PhD and project supervision)</p> <p>2019: Science Communication Project, Austrian Science Fund (FWF WKP 132-B: 49,083 €; “Art4Science”, 05/2020-04/2022, project lead)</p> <p>2018: Stand-Alone Project, Austrian Science Fund (FWF P32001-B; 341,760 €; “Finding tumor immune evasions strategies by cellular barcoding”; 03/2019-09/2023, project lead)</p> <p>2014: Erwin Schrödinger Fellowship, Austrian Science Fund (FWF J3635; 156,940 €; “NLRP1 and NLRP3 in T and NK cell immunity”; 02/2015-03/2018, project lead)</p> <p>2008: DOC-fORTE, Austrian Academy of Science (60,000 €; “STAT1 Serine727 – Key Regulator for NK Cell-Mediated Cytotoxicity and Tumor Surveillance”; 01/2010-12/2011; project lead)</p>
<i>Awards</i>	<p>2022: Heribert-Konzett-Prize of the Austrian Pharmacological Society (APHAR)</p> <p>2022: Best talk at the 14th ÖGMBT Annual Meeting, Vienna, Austria</p> <p>2014: Poster prize at the 6th ÖGMBT Annual Meeting, Vienna, Austria</p> <p>2014: Armin Tschermak von Seysenegg Prize, Gesellschaft der Freunde der VUW</p> <p>2013: EFIS scholarship, 2nd Meeting of Mid-Europ. Soc. f. Immunol. and Allergol., Croatia</p> <p>2011: EFIS-EJI scholarship for EMBO - Signaling in the Immune System Meeting in Siena, Italy</p> <p>2009: Poster prize at the Natural Killer Cell Symposium in Freiburg, Germany</p>
<i>Oral Presentations</i>	<p>2023: - Seminar at the Fondazione Ri.MED, Palermo, Italy - CACB Seminar at the Center for Anatomy and Cell Biology, MUW, Austria</p> <p>2022: - Keynote lecture at the 26th Annual Meeting of the APHAR in Graz, Austria - 14th ÖGMBT Meeting, Vienna, Austria - Series “Being up to date in cancer biology” at the VetMedUni Vienna, Austria</p> <p>2021: Karl Landsteiner Lunchtime seminar, virtual</p> <p>2020: Science Meeting at the Institute of Physiology, Medical University of Vienna, Austria</p> <p>2019: LBI for Hematology and Oncology KickOff Meeting, Austria</p> <p>2014: NK2014 Meeting, Germany</p> <p>2013: 2nd Meeting of Middle-Europ. Soc. f. Immunol. & Allergol. Croatia</p> <p>2013: 19th Scientific Symposium of APHAR, Austria</p> <p>2010: Annual Meeting of the Austrian Society for Allergology and Immunology (ÖGAI), Vienna, Austria</p> <p>2008: 4th PhD Symposium, Austria</p>
<i>Memberships</i>	<p>APHAR (Austrian Pharmacological Society, since 2008)</p> <p>EATI (European Academy of Tumor Immunology, since 2016)</p> <p>OEGAI (Austrian Society for Allergology and Immunology, since 2011)</p> <p>OEGMBT (Austrian Association of Molecular Life Sciences and Biotechnology, since 2013)</p>
<i>Peer-Review activities</i>	<p><i>Journals:</i> Animal Biotechnology, Cancer Research, Frontiers in Immunology, Journal of ImmunoTherapy of Cancer, Journal of Medicinal Chemistry, Molecules, OncoImmunology, PlosOne, Trends in Immunology; <i>Funding Bodies:</i> Children’s Cancer and Leukaemia Group (CCLG), Grace Kelly Childhood Cancer Trust</p>
<i>Editorial activities</i>	<p>2021-2022: Topic editor of “Drivers of Innate Lymphoid Cell Plasticity” in Frontiers in Immunology</p>
<i>Collaboration partners</i>	<p>Emilio Casanova, Matthias Farlik, Thorsten Füreder, Dietmar Herndler-Brandstetter, Johannes Huppa, Xaver König, Christoph Minichsdorfer, Herwig Moll, Shinya Sakaguchi, Isabella Salzer, Gernot Schabbauer, Eva Zebedin-Brandl (MUW, Austria); Martin Distel, Manfred Lehner, Sabine Strehl, etc. (CCRI, Austria); Dagmar Gotthardt, Veronika Sexl (Vetmeduni, Austria); Dagmar Stoiber-Sakaguchi, Agnieszka Witalisz-Siepracka (KL University Krems, Austria); Anna Obenauf (IMP, Austria); Michael Traxlmayr, Charlotte Zajc (BOKU, Austria); Tobias Bald, Dillon Corvino (University of Bonn, Germany); Leila Perié (Institut Curie, France); Ton Schumacher (NKI, The Netherlands); Eric Kowarz, Rolf Marschalek (University of Frankfurt, Germany); Melissa Elliott, Todd A. Fehniger (Washington University in St. Louis, USA); Debby Hynx, Fengyuan Tang (University of Basel, Switzerland); Juming Yan (Xuzhou Medical University, China)</p>

SCIENCE COMMUNICATION ACTIVITIES

<i>Science Communication</i>	<p>since 2020: Art4Science project (https://www.art4science.at/) 2019-2023: Lange Nacht der Kinderkrebsforschung, CCRI 2018: BE OPEN Science & Society Festival of the FWF</p>
<i>Teaching</i>	<p>2020 WS: MUW, Austria: "Spot Lights on Paediatric Cancer Research" (SE) 2017 SS: Vetmeduni Vienna, Austria: "Neue Therapieansätze in der Tumorthherapie" (SE) 2016: QIMR Berghofer Institute, Australia: "High school work experience program" (SE+PR) 2014 WS: MUW, Austria: Basic seminar "NK cells – what is new in the field" in the PhD thematic program "Inflammation and Immunity" (SE) 2007 SS: University of Vienna, Austria: "Laboratory Course C + Molecular Biology II" (PR)</p>
<i>Supervision</i>	<p>Bachelor student: Lisa Sippl (2023) Master students: Kevin Kos (2016), Susanne Stofner (2021), Alma Dupanovic (2023) PhD students: Michelle Buri (2020-current), Faith David (2021-current) (MUW, N094, Thematic Program: "Malignant Diseases") Co-supervision of numerous Master and PhD students Postdoctoral fellow: Dr. Charlotte Zajc (2023-current, University of BoKu, official mentor through ESPRIT, FWF)</p>
<i>Extracurricular activities</i>	<p>PhD committee member of Julia List (Vetmeduni, 2022-current), PhD examiner of Fehmke Ehlers (University of Maastricht, 01/2023) Master thesis reviewer and examiner of Carina Mühlberger (Vetmeduni, 09/2021)</p>
<i>Meetings – Poster Presentations (excerpt)</i>	<p>2016: International Congress of Immunology (ICI), Melbourne, Australia: <u>E.M. Putz</u>, F. Souza-Fonseca-Guimaraes, D.S. Barkauskas, L. Town, M.D. Hulett, M.J. Smyth. "The role of heparanase in NK cell migration and NK cell-mediated tumour surveillance" 2015: Immunotherapy@Brisbane, Brisbane, Australia: <u>E.M. Putz</u>, F. Souza-Fonseca-Guimaraes, D.S. Barkauskas, L. Town, M.D. Hulett, M.J. Smyth. "The role of heparanase in NK cell migration and NK cell-mediated tumour surveillance" 2015: 1st Australian Innate Lymphocyte Symposium, Melbourne, Australia: <u>E.M. Putz</u>, A. Majoros, D. Gotthardt, T. Decker and V. Sexl. "Novel non-canonical role of STAT1 in Natural Killer cell cytotoxicity" 2012: Natural Killer cell Symposium NK2012, Heidelberg, Germany: <u>E.M. Putz</u>, D. Gotthardt, D. Stoiber, T. Decker and V. Sexl, "Stat1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance" 2011: EMBO Conference: Signaling in the Immune System, Siena, Italy: <u>E.M. Putz</u>, E.M. Zebedin-Brandl, M. Prchal, T. Decker and V. Sexl, "STAT1 Serine727 – License to Kill" 2009: Natural Killer cell Symposium NK2009, Freiburg, Germany: <u>E.M. Putz</u>, E.M. Zebedin, A. Csiszar, M. Prchal, T. Decker, P. Kovarik and V. Sexl, "STAT1-Serine727 – Key regulator for NK cell mediated cytotoxicity and tumor surveillance" 2009: 15th International Summer School on Immunology (FEBS), Hvar, Croatia: <u>E.M. Putz</u>, E. Zebedin, A. Csiszar, M. Prchal, A. Berger, T. Decker, P. Kovarik and V. Sexl, "STAT1-S727 - Key regulator for NK cell-mediated cytotoxicity and tumor surveillance"</p>

MAIN AREAS OF RESEARCH

For the last 16 years, I have worked in the field of tumor immunology, starting as a PhD student in the laboratory of Veronika Sexl (MUW and Vetmeduni Vienna) and proceeding as a postdoctoral fellow in the laboratory of Mark Smyth at the QIMR Berghofer Institute of Medical Research in Brisbane (Australia).

The focus of my studies has always been to increase our knowledge about how to improve the anti-tumor functions of cytotoxic immune cells such as natural killer and T cells. By using gene-modified mice, a multitude of *in vivo* tumor models and an extensive range of *in vitro* assays (e.g. multi-color flow cytometry, molecular biology and functional assays, cellular barcoding, primary cell transduction, gene knockdown and knockout, mass spectrometry, etc.) I have contributed to the discovery of exciting novel ways of enhancing NK cell-mediated tumor surveillance (e.g. blocking CDK8-mediated STAT1-S727 phosphorylation or CIS-mediated downregulation of IL-15 signaling) and highlighted the potential drawback of drugs that interfere with NK cell migration (heparanase inhibitors) or T cell function (PI3Kδ inhibitors).

My training in excellent and internationally renowned laboratories allowed me to collaborate with highly ranked scientists all over the world and to publish 1 book chapter, 6 reviews and 31 original peer-reviewed papers.

PUBLICATIONS (published under my maiden name E.M. Putz)

citations: 2151; h-index: 25

1. D. Yuan, J. Hu, X. Ju, E.M. Putz, S. Zheng, G. Sun, S. Koda, Z. Xu, W. Nie, S. Shao, Y. Chen, R. Tang, K.-Y. Zheng, J. Yan. NMDAR antagonists suppressed tumor progression by regulating tumor-associated macrophages. *PNAS*, PMID: 37967215, Nov. 2023
2. B. Hackl, E. Zabrodzka, S. Gewessler, E. Liliu, E.M. Putz, A. Kiss, B. Podesser, H. Todt, R. Ristl, K. Hilber, X. Koenig. The type of suture material affects transverse aortic constriction-induced heart failure development in mice: a repeated measures correlation analysis. *Frontiers Cardiovascular Medicine*, PMID: 37795481, Sep. 2023
3. S. Grissenberger, C. Sturtzel, A. Wenninger-Weinzierl, B. Radic-Sarikas, E. Scheuringer, L. Bierbaumer, V. Etienne, F. Némati, S. Pascoal, M. Tötzl, E. Tomazou, M. Metzelder, E.M. Putz, D. Decaudin, O. Delattre, D. Surdez, H. Kovar, F. Halbritter, M. Distel. High-content drug screening in zebrafish xenografts reveals high efficacy of dual MCL-1/BCL-X_L inhibition against Ewing sarcoma. *Cancer Letters*, PMID: 36462556, Feb. 2023
4. T. Fuereder, C. Minichsdorfer, M. Mittlboeck, C. Wagner, G. Heller, E.M. Putz, F. Oberndorfer, L. Müllauer, M.-B. Aretin, C. Czerny, U. Schwarz-Nemec. Pembrolizumab plus docetaxel for the treatment of recurrent/metastatic head and neck cancer: A prespective phase I/II study. *Oral Oncology*, PMID: 34844042, Jan. 2022
5. B. Salzer, C.M. Schueller, C.U. Zajc, T. Peters, M.A. Schoeber, B. Kovacic, M.C. Buri, E. Lobner, O. Dushek, J.B. Huppa, C. Obinger, E.M. Putz, W. Holter, M.W. Traxlmayr, M. Lehner. Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function. *Nature Communications*, PMID: 32820173, Aug. 2020
6. D. Prinz, K. Klein, J. List, V.M. Knab, I. Menzl, N. Leidenfrost, G. Heller, B. Polić, E.M. Putz, A. Witalisz-Siepracka, V. Sexl, D. Gotthardt. Loss of NKG2D in Murine NK Cells Leads to Increased Perforin Production Upon Long-Term Stimulation With IL-2. *European Journal of Immunology*, PMID: 32052406, Feb. 2020
7. D. Gotthardt, J. Trifinopoulos, V. Sexl, E.M. Putz. JAK/STAT Cytokine Signaling at the Crossroad of NK Cell Development and Maturation. *Frontiers in Immunology*, PMID: 31781102, Nov. 2019
8. E. Porpacz*, S. Tripolt*, A. Hoelbl-Kovacic*, B. Gisslinger, Z. Bago-Horvath, E. Casanova-Hevia, T. Decker, S. Fajmann, D.A. Fux, S. Gueltekin, G. Heller, H. Herkner, T. Kolbe, E.M. Putz, C. Kornauth, M. Mueller, M. Prchal-Murphy, A.-I. Schiefer, C. Schneckenleithner, C. Skrabs, W.R. Sperr, B. Strobl, P. Valent, R. Kralovics, L. Muellauer, I. Simonitsch-Klupp, E. Cappier, E. Raffoux, J.-J. Kiladjian, M.-T. Krauth, P.B. Staber, G. Greiner, G. Hoermann, U. Jaeger*, H. Gisslinger* and V. Sexl*. Aggressive B-cell Lymphomas in Patients With Myelofibrosis Receiving JAK1/2 Inhibitor Therapy. *Blood*, PMID: 29907599, Aug. 2018
9. K. Nakamura, S. Kassem, A. Cleynen, M.-L. Chrétien, C. Guillerey, E.M. Putz, T. Bald, I. Förster, S. Vuckovic, G.R. Hill, S.L. Masters, M. Chesi, P.L. Bergsagel, H. Avet-Loiseau, L. Martinet* and M.J. Smyth*. Dysregulated IL-18 is a key driver of immunosuppression and a possible therapeutic target in the multiple myeloma microenvironment. *Cancer Cell*, PMID: 29551594, Mar. 2018
10. A. Witalisz-Siepracka*, D. Gotthardt*, M. Prchal-Murphy, Z. Didara, I. Menzl, D. Prinz, L. Edlinger, E.M. Putz, V. Sexl. NK cell-specific CDK8 deletion enhances antitumor responses. *Cancer Immunology Research*, PMID: 29386186, Jan. 2018
11. D. Mittal, D. Vijayan, E.M. Putz, A. Roman Aguilera, K. Markey, J. Straube, S. Kazakoff, S. Nutt, K. Takeda, G. Hill, N. Waddell, and M.J. Smyth. NK cell suppression of metastasis partially requires CD103⁺ Batf3-dependent dendritic cells and interleukin-12. *Cancer Immunology Research*, PMID: 29070650, Oct. 2017
12. E.M. Putz, A. Mayfosh, K. Kos, D.S. Barkauskas, L. Town, K.J. Goodall, D.Y. Yee, I.K.H. Poon, N. Baschuk, F. Souza-Fonseca-Guimaraes, M. Hulett* and M.J. Smyth*. Natural killer cell heparanase controls tumor invasion and immune surveillance. *Journal of Clinical Investigations*, PMID: 28581441, June 2017
13. E.M. Putz, C. Guillerey, K. Kos, K. Stannard, K. Miles, R.B. Delconte, K. Takeda, S.E. Nicholson, N. D. Huntington, M.J. Smyth. Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis. *Onc Immunology*, PMID: 28344878, Feb. 2017
14. R. Klose, E. Krzywinska, M. Castells, D. Gotthardt, E.M. Putz, C. Kantari-Mimoun, N. Chikdene, A.K. Meinecke, K. Schrödter, I. Helfrich, J. Fandrey, V. Sexl, C. Stockmann. Targeting VEGF-A in myeloid cells enhances natural killer cell responses to chemotherapy and ameliorates cachexia. *Nature communications*, PMID: 27538380, Aug. 2016
15. E.M. Putz, A. Majoros, D. Gotthardt, M. Prchal-Murphy, E.M. Zebedin-Brandl, D.A. Fux, A. Schlattl, R.D. Schreiber, S. Carotta, M. Müller, C. Gerner, T. Decker* and V. Sexl*. Novel non-canonical role of STAT1 in Natural Killer cell cytotoxicity. *Onc Immunology*, PMID: 27757297, May 2016

PUBLICATIONS (continued)

16. R.B. Delconte*, T.B. Kolesnik*, L.F. Dagley*, J. Rautela, W. Shi, E.M. Putz, K. Stannard, J.G. Zhang, C. Teh, M. Firth, T. Ushiki, C. Andoniou, M.A. Degli-Esposti, P.P. Sharp, C.E. Sanvitale, G. Infusini, N.P. Liao, E.M. Linossi, C.J. Burns, S. Carotta, D.H. Gray, C. Seillet, D.S. Hutchinson, G.T. Belz, A.I. Webb, W.S. Alexander, S.S. Li, A.N. Bullock, J.J. Babon, M.J. Smyth, S.E. Nicholson*, N.D. Huntington*. CIS is a potent checkpoint in NK cell-mediated tumor immunity. *Nature Immunology*, PMID: 27213690, May 2016; **CORRECTION (Dec. 2023)**
17. D. Gotthardt, E.M. Putz, E. Grundschober, M. Prchal-Murphy, E. Straka, P. Kudweis, G. Heller, Z. Bago-Horvath, A. Witalisz-Siepracka, A.A. Cumaraswamy, P.T. Gunning, B. Strobl, M. Mueller, R. Moriggl, C. Stockmann, V. Sexl. STAT5 is a key regulator in NK cells and acts as molecular switch from tumor surveillance to tumor promotion. *Cancer Discovery*, PMID: 26873347, Feb. 2016
18. Y. Krasnova, E.M. Putz, M.J. Smyth, F. Souza-Fonseca-Guimaraes. Bench to bedside: NK cells and control of metastasis. *Clinical Immunology*, PMID: 26476139, Oct. 2015
19. M. Prchal-Murphy*, A. Witalisz-Siepracka*, K.T. Bednarik, E.M. Putz, D. Gotthardt, K. Meissl, V. Sexl, M. Müller, B. Strobl. *In vivo* tumor surveillance by NK cells requires TYK2 but not TYK2 kinase activity. *Oncolmmunology*, PMID: 26451322, July 2015
20. P. Pathria, D. Gotthardt*, M. Prchal-Murphy*, E.M. Putz*, M. Holcman, M. Schleder, B. Grabner, I. Crncec, J. Svinka, M. Musteanu, T. Hoffmann, M. Filipits, W. Berger, V. Poli, L. Kenner, M. Bilban, E. Casanova, M. Müller, B. Strobl, E. Bayer, T. Mohr, V. Sexl, R. Eferl. Myeloid STAT3 promotes formation of colitis-associated colorectal cancer in mice. *Oncolmmunology*, PMID: 26137415, Jan. 2015
21. E.M. Putz, D. Gotthardt, V. Sexl. STAT1-S727 - the license to kill. *Oncolmmunology*, PMID: 25941617, Dec. 2014
22. D. Gotthardt, M. Prchal-Murphy, C. Seillet, A. Glasner, O. Mandelboim, S. Carotta, V. Sexl, E.M. Putz. NK cell development in bone marrow and liver - site matters. *Genes & Immunity*, PMID: 25319498, Oct. 2014
23. D. Gotthardt, E.M. Putz, E. Straka, P. Kudweis, M. Biaggio, V. Poli, B. Strobl, M. Müller, V. Sexl. Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. *Blood*, PMID: 25185262, Sept. 2014
24. G. Hoermann, K. Blatt, G. Greiner, E.M. Putz, A. Berger, H. Herrmann, S. Cerny-Reiterer, K.V. Gleixner, C. Walz, K. Hoetzenecker, L. Müllauer, A. Reiter, K. Sotlar, V. Sexl, P. Valent, M. Mayerhofer. CD52 is a molecular target in advanced systemic mastocytosis. *FASEB J.*, PMID: 24760752, Apr. 2014
25. E.M. Putz, M.A. Hoelzl, J. Baeck, Z. Bago-Horvath, C. Schuster, B. Reichholf, D. Kern, F. Aberger, V. Sexl, A. Hoelbl-Kovacic. Loss of STAT3 in Lymphoma Relaxes NK Cell-Mediated Tumor Surveillance. *Cancers*, PMID: 24473086, Jan. 2014
26. A. Berger, A. Hoelbl-Kovacic, J. Bourgeais, L. Hoefling, W. Warsch, E. Grundschober, I.Z. Uras, I. Menzl, E.M. Putz, G. Hoermann, C. Schuster, S. Fajmann, E. Leitner, S. Kubicek, R. Moriggl, F. Gouilleux, V. Sexl. PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis. *Leukemia*, PMID: 24263804, Nov. 2013
27. E.M. Putz, D. Gotthardt, G. Hoermann, A. Csiszar, S. Wirth, A. Berger, E. Straka, D. Rigler, B. Wallner, A.M. Jamieson, W.F. Pickl, E. Zebedin-Brandl, M. Müller, T. Decker and V. Sexl. CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance. *Cell Reports*, PMID: 23933255, Aug. 2013
28. A.D. Köprülü, R. Kastner, S. Wienerroither, C. Lassnig, E.M. Putz, O. Majer, B. Reutterer, V. Sexl, K. Kuchler, M. Müller, T. Decker and W. Ellmeier. The Tyrosine Kinase Btk Regulates the Macrophage Response to Listeria monocytogenes Infection. *PLoS ONE*, PMID: 23544144, Mar. 2013
29. M. Prchal-Murphy*, E.M. Putz*, M. Freissmuth, V. Sexl and E. Zebedin-Brandl. Targeting PI3K δ - One man's meat is another man's poison. *Oncolmmunology*, PMID: 23482629, Jan. 2013
30. T. Mizutani*, N. Neugebauer*, E.M. Putz*, N. Moritz, O. Simma, E. Zebedin-Brandl, D. Gotthardt, W. Warsch, E. Eckelhart, H.P. Kantner, U. Kalinke, S. Lienenklaus, S. Weiss, B. Strobl, M. Müller, V. Sexl and D. Stoiber. Conditional IFNAR1 ablation reveals distinct requirements of type I IFN signaling for NK cell maturation and tumor surveillance. *Oncolmmunology*, PMID:23170251, Oct. 2012
31. E.M. Putz, C. Schuster and V. Sexl. Bcl-2: Live and let die. *Oncolmmunology*, PMID: 22934270, Aug. 2012
32. E.M. Putz*, M. Prchal-Murphy*, O.A. Simma, F. Forster, X. Koenig, H. Stockinger, R.P. Piekorz, M. Freissmuth, M. Müller, V. Sexl and E. Zebedin-Brandl. PI3K δ Is Essential for Tumor Clearance Mediated by Cytotoxic T Lymphocytes. *PLoS ONE*, PMID: 22808277, Jul. 2012
33. E.M. Putz, E. Zebedin and V. Sexl. STAT Transcription Factors: Controlling All Aspects of NK Cell Biology. (bookchapter, p. 187-204) in the book: Jak-Stat Signaling: From Basics to Disease, editors T. Decker and M. Müller; *Springer, Online: ISBN 978-3-7091-0891-8, Jun. 2012*

PUBLICATIONS (continued)

34. C. Schuster*, A. Berger*, M.A. Hoelzl, E.M. Putz, A. Frenzel, O. Simma, N. Moritz, A. Hoelbl, B. Kovacic, M. Freissmuth, M. Müller, A. Villunger, L. Müllauer, A.I. Schmatz, E. Porpaczy, U. Jäger, D. Stoiber and V. Sexl. The cooperating mutation or “second hit” determines the immunological visibility towards MYC-induced murine lymphomas. **Blood**, PMID: 21878673, Aug. 2011
35. A.A. Vitale, A.B. Pomilio, C.O. Cañellas, M.G. Vitale, E.M. Putz and J. Ciprian-Ollivier. In Vivo Long-Term Kinetics of Radiolabeled *N,N*-Dimethyltryptamine and Tryptamine. **Journal of Nuclear Medicine**, PMID: 21622895, Jun. 2011
36. O. Simma, E. Zebedin, N. Neugebauer, C. Schellack, A. Pilz, S. Chang-Rodriguez, K. Lingnau, E. Weisz, E.M. Putz, W.F. Pickl, T. Felzmann, M. Müller, T. Decker, V. Sexl and D. Stoiber. Identification of an Indispensable Role for Tyrosine Kinase 2 in CTL-Mediated Tumor Surveillance. **Cancer Research**, PMID: 19118004, Jan. 2009
37. E. Zebedin, O. Simma, C. Schuster, E.M. Putz, S. Fajmann, W. Warsch, E. Eckelhart, D. Stoiber, E. Weisz, J.A. Schmid, W.F. Pickl, C. Baumgartner, P. Valent, R.P. Piekorz, M. Freissmuth and V. Sexl. Leukemic challenge unmasks a requirement for *PI3Kδ* in NK-cell-mediated tumor surveillance. **Blood**, PMID: 18684865, Aug. 2008

* ... contributed equally